0 CHECKOUT

Restenosis - Pipeline Review, H2 2015

  • ID: 3446783
  • September 2015
  • 59 pages
  • Global Markets Direct
1 of 3

Restenosis - Pipeline Review, H2 2015

Summary

The report ‘Restenosis - Pipeline Review, H2 2015’, provides an overview of the Restenosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Restenosis Overview

Therapeutics Development

Pipeline Products for Restenosis - Overview

Pipeline Products for Restenosis - Comparative Analysis

Restenosis - Therapeutics under Development by Companies

Restenosis - Therapeutics under Investigation by Universities/Institutes

Restenosis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Restenosis - Products under Development by Companies

Restenosis - Products under Investigation by Universities/Institutes

Restenosis - Companies Involved in Therapeutics Development

advanceCor GmbH

Bio3 Research S.r.l

CSPC Pharmaceutical Group Limited

CytoTools AG

Shire Plc

XBiotech USA, Inc.

Restenosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Annexin A-5 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

butylphthalide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

COR-3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CT-406 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CV-18C3 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Didox - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HMW-02Ak - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HMW-02Ap - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HO-3867 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PVS-10200 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VAN 10-4 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Restenosis - Recent Pipeline Updates

Restenosis - Dormant Projects

Restenosis - Discontinued Products

Restenosis - Product Development Milestones

Featured News & Press Releases

Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis

Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease

Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites

Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Restenosis, H2 2015

Number of Products under Development for Restenosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Restenosis - Pipeline by advanceCor GmbH, H2 2015

Restenosis - Pipeline by Bio3 Research S.r.l, H2 2015

Restenosis - Pipeline by CSPC Pharmaceutical Group Limited, H2 2015

Restenosis - Pipeline by CytoTools AG, H2 2015

Restenosis - Pipeline by Shire Plc, H2 2015

Restenosis - Pipeline by XBiotech USA, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Restenosis Therapeutics - Recent Pipeline Updates, H2 2015

Restenosis - Dormant Projects, H2 2015

Restenosis - Dormant Projects (Contd..1), H2 2015

Restenosis - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Restenosis, H2 2015

Number of Products under Development for Restenosis - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Cytori Therapeutics, Inc.
  • Pfizer Inc.
  • Medtronic, Inc.
  • St. Jude Medical, Inc.
  • Novo Nordisk A/S
  • Lumedx